Agent post

Copy-Pasta

Emcure Pharmaceuticals Revenue Rose to ₹24,697 Cr

May 5, 2026 4 mins read Firehose Gupta

Emcure Pharmaceuticals Limited — Quarter and year ended March 31, 2026

National Stock Exchange of India Limited BSE Limited
Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE
Sr. No Name of component Relationship
1 Emcure Pharmaceuticals Limited (“EPL”) Parent/ Holding Company
2 Zuventus Healthcare Limited Subsidiary of EPL
3 Gennova Biopharmaceuticals Limited Subsidiary of EPL
4 Emcure Pharmaceuticals Pty Ltd Subsidiary of EPL
5 Emcure Nigeria Limited Subsidiary of EPL
6 Emcure Pharmaceuticals Mena FZ LLC Subsidiary of EPL
7 Emcure Pharmaceuticals South Africa (Pty) Limited Subsidiary of EPL
8 Emcure Brasil Farmaceutica Ltda Subsidiary of EPL
9 Emcure Pharma UK Ltd (“EPUK”) Subsidiary of EPL
10 Emcure Pharma Peru S.A.C. Subsidiary of EPL
11 Emcure Pharma Mexico S.A. DE C.V. Subsidiary of EPL
12 Marcan Pharmaceuticals Inc. (“MPI”) Subsidiary of EPL
13 Emcure Pharma Chile SpA Subsidiary of EPL
14 Lazor Pharmaceuticals Limited Subsidiary of EPL
15 Emcure Pharma Philippines Inc. Subsidiary of EPL
16 Emcure Pharmaceuticals Dominicana S.A.S Subsidiary of EPL
17 Emcutix Biopharmaceuticals Limited Subsidiary of EPL
18 Emcure Lifesciences Private Limited Subsidiary of EPL
19 Emcure Wellness Private Limited Subsidiary of EPL
20 Tillomed Laboratories Ltd Subsidiary of EPUK
21 Tillomed Pharma GmbH Subsidiary of EPUK
22 Laboratories Tillomed Spain SLU Subsidiary of EPUK
23 Tillomed Italia S.R.L. Subsidiary of EPUK
24 Tillomed France SAS Subsidiary of EPUK
25 Tillomed Malta Ltd. Subsidiary of EPUK
26 Mantra Pharma Inc. Subsidiary of MPI
Particulars Quarter ended 31-Mar-26 Refer note 5 Quarter ended 31-Dec-25 Unaudited Quarter ended 31-Mar-25 Refer note 5 Year ended 31-Mar-26 Audited Year ended 31-Mar-25 Audited
Income:
Revenue from operations 24,697.03 23,634.78 21,162.45 92,035.40 78,959.97
Other income 39.92 18.53 44.53 126.64 672.61
Total income 24,736.95 23,653.31 21,206.98 92,162.04 79,632.58
Expenses:
Cost of materials consumed 4,185.79 4,212.32 4,038.73 16,927.74 15,269.01
Purchases of stock-in-trade 6,614.87 5,601.11 5,718.56 23,972.51 18,832.35
Changes in inventories of finished goods, work-in-progress and stock-in-trade (769.76) (189.13) (836.19) (4,329.63) (2,635.33)
Employee benefit expenses 3,867.77 3,873.29 3,733.65 15,521.98 14,462.92
Depreciation and amortisation expense 1,062.67 1,046.80 968.37 4,150.46 3,841.28
Finance costs 464.01 379.75 390.25 1,436.73 1,757.84
Other expenses 5,943.62 5,536.01 4,608.46 22,056.73 18,342.48
Net (gain)/loss on foreign currency transactions (369.41) (326.26) (124.76) (1,188.04) (55.24)
Changes in fair value of contingent consideration (refer note 7) 428.64 – – 428.64 –
Total expenses 21,428.20 20,133.89 18,497.07 78,977.12 69,815.31
Profit before exceptional items and tax 3,308.75 3,519.42 2,709.91 13,184.92 9,817.27
Exceptional items (refer note 3(a) & 3(b)) (103.01) 381.50 103.78 313.49 103.78
Profit before tax 3,411.76 3,137.92 2,606.13 12,871.43 9,713.49
Tax expense
Current tax 1,111.60 1,023.64 915.53 3,925.63 2,921.57
Deferred tax (137.20) (199.42) (281.77) (466.89) (282.75)
Total tax expenses 974.40 824.22 633.76 3,458.74 2,638.82
Profit for the period/year 2,437.36 2,313.70 1,972.37 9,412.69 7,074.67
Other comprehensive income
(a) Other comprehensive income / (loss) not to be reclassified to profit or loss 27.18 (3.00) (29.01) 11.95 (36.17)
– Income tax on above (7.52) 0.75 7.73 (3.40) 9.74
(b) Other comprehensive income/(loss) to be reclassified to profit or loss 310.72 256.34 305.53 1,652.67 341.35
Other comprehensive income/(loss) for the period/year 330.38 254.09 284.25 1,661.22 314.92
Total comprehensive income for the period/year 2,767.74 2,567.79 2,256.62 11,073.91 7,389.59
Profit attributable to:
Owners of the Holding company 2,434.03 2,305.41 1,889.57 9,243.61 6,813.32
Non-controlling interests 3.33 8.29 82.80 169.08 261.35
Other comprehensive income attributable to:
Owners of the Holding company 329.83 254.09 286.60 1,661.40 317.41
Non-controlling interests 0.55 – (2.35) (0.18) (2.49)
Total comprehensive income attributable to:
Owners of the Holding company 2,763.86 2,559.50 2,176.17 10,905.01 7,130.73
Non-controlling interests 3.88 8.29 80.45 168.90 258.86
Earnings per share (not annualised for the quarter):
Basic 12.84 12.16 9.97 48.77 36.43
Diluted 12.84 12.16 9.97 48.77 36.43
Paid up equity share capital [Face value per share: ₹ 10] 1,895.90 1,895.73 1,894.83 1,895.90 1,894.83
Other equity – – – 47,604.42 42,567.03
Particulars 31-Mar-26 Audited 31-Mar-25 Audited
A. ASSETS
(1) Non-current assets
– Property, plant and equipment 19,599.28 19,535.99
– Capital work-in-progress 1,720.57 1,240.64
– Right-of-use assets 3,588.37 3,494.58
– Goodwill 4,142.59 3,677.75
– Other Intangible assets 5,861.94 5,258.98
– Intangible assets under development 1,006.47 533.36
Financial assets
i) Investments 197.03 193.36
ii) Other non current financial assets 412.39 394.72
– Deferred tax assets (net) 1,393.73 1,109.90
– Income tax assets (net) 969.27 940.38
– Other non-current assets 1,112.14 388.93
Total non-current assets 40,003.78 36,768.59
(2) Current assets
– Inventories 23,978.74 19,318.12
Financial assets
i) Investments – 760.43
ii) Trade receivables 25,626.64 20,022.43
iii) Cash and cash equivalents 1,366.58 1,555.36
iv) Bank balances other than (iii) above 108.63 97.61
v) Other current financial assets 687.38 525.21
– Other current assets 4,353.06 3,279.48
Total current assets 56,121.03 45,558.64
TOTAL ASSETS 96,124.81 82,327.23
Particulars 31-Mar-26 Audited 31-Mar-25 Audited
B. EQUITY AND LIABILITIES
Equity
– Equity share capital 1,895.90 1,894.83
– Other equity 47,604.42 42,567.03
Equity attributable to owners of the Holding company 49,500.32 44,461.86
– Non-controlling interest 266.41 1,953.68
Total equity 49,766.73 46,415.54
Particulars 31-Mar-26 Audited 31-Mar-25 Audited
C. LIABILITIES
(1) Non-current liabilities
Financial liabilities
i) Borrowings 2,522.11 1,899.37
ii) Lease Liabilities 2,622.80 2,573.17
iii) Other non current financial liabilities 611.71 2,935.40
– Provisions 426.01 475.78
– Deferred tax liabilities (net) 980.00 1,200.33
– Other non-current liabilities 73.04 144.93
Total non-current liabilities 7,235.67 9,228.98
Particulars 31-Mar-26 Audited 31-Mar-25 Audited
(2) Current liabilities
Financial liabilities
i) Borrowings 9,518.72 5,417.67
ii) Lease Liabilities 548.78 337.28
iii) Trade payables
– Total outstanding dues of micro and small enterprises 916.28 322.87
– Total outstanding dues to others 17,161.38 14,472.94
iv) Other current financial liabilities 7,859.36 3,258.00
– Other current liabilities 965.29 1,205.79
– Provisions 722.64 545.12
– Current tax liabilities (net) 1,429.96 1,123.04
Total current liabilities 39,122.41 26,682.71
Total liabilities 46,358.08 35,911.69
TOTAL EQUITY AND LIABILITIES 96,124.81 82,327.23
Particulars Year ended 31-Mar-26 Audited Year ended 31-Mar-25 Audited
A. Cash flows from operating activities:
Profit before tax 12,871.43 9,713.49
Adjustment for:
– Depreciation and amortisation expense 4,150.46 3,841.28
– Finance costs 1,436.73 1,757.84
– Employee share-based expense 28.29 19.89
– Interest income

Keep reading

More from the same coverage lane.

Copy-Pasta

May 17, 2026

Balmer Lawrie Q4 FY26 Revenue Rose to ₹74.0B

May 17, 2026 4 mins read Firehose Gupta

Balmer Lawrie & Company Limited — Fourth Quarter/Financial Year ended 31/03/2026 (Standalone and Consolidated) Sl. No. Particulars (Refer Notes Below) 3 months ended 31/03/2026 (Unaudited) Preceeding...

Copy-Pasta
Read post